- Legend Biotech recently reported first-quarter 2026 results, with revenue rising to US$305.1 million from US$195.0 million a year earlier and net loss narrowing to US$54.3 million from US$101.0 million.
- Ahead of and during the 2026 ASCO Meeting, the company also released early clinical data for its DLL3-targeted CAR-T LB2102 and new CARVYKTI analyses, underlining progress across both its lung cancer and multiple myeloma programs.
- We’ll now explore how the new LB2102 Phase 1 data and expanded CARVYKTI evidence might influence Legend Biotech’s broader investment narrative.
Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
Legend Biotech Investment Narrative Recap
To own Legend Biotech, you need to believe CARVYKTI can support the business while a broader cell therapy pipeline matures, and that losses can keep narrowing. The latest Q1 2026 results and ASCO data support that basic story but do not materially change the near term focus on CARVYKTI performance as the key catalyst, or the concentration and profitability risks tied to that single product.
Among the recent updates, the preliminary Phase 1 data for LB2102 at ASCO 2026 looks most relevant, because it speaks directly to Legend’s effort to reduce reliance on CARVYKTI by advancing a solid tumor program in small cell lung cancer and large cell neuroendocrine carcinoma. How quickly and convincingly LB2102 progresses could influence how investors weigh CARVYKTI concentration risk against the emerging pipeline.
Yet beneath the encouraging progress, investors should also be aware of growing competition and pricing pressure that could...
Read the full narrative on Legend Biotech (it's free!)
Legend Biotech's narrative projects $2.1 billion revenue and $501.1 million earnings by 2029. This requires 27.3% yearly revenue growth and an earnings increase of about $798 million from -$296.8 million today.
Uncover how Legend Biotech's forecasts yield a $57.24 fair value, a 95% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already modeling Legend to reach about US$2.7 billion in revenue and US$869.2 million in earnings by 2029, so if you focus on how quickly CARVYKTI ramps or how LB2102 evolves, you can see how opinions differ sharply and why this new information could shift those expectations in very different directions.
Explore 7 other fair value estimates on Legend Biotech - why the stock might be worth 28% less than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Legend Biotech research is our analysis highlighting 1 key reward that could impact your investment decision.
- Our free Legend Biotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Legend Biotech's overall financial health at a glance.
Ready For A Different Approach?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- Explore 28 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com